JAK2 and myeloproliferative disorder: It should be noted that in order to demonstrate an augmented or synergistic effect of combining PIM and JAK2 inhibition to enhance the efficacy of targeting MPN cells, the dose of ruxolitinib we utilized in our studies was suboptimal for the effect under investigation (e.g. decrease in phosphorylation of biomarkers, apoptosis induction, etc.).